• Kelun-Biotech flagged multiple Phase 3 sacituzumab tirumotecan studies as late-breaking oral presentations at ESMO 2026 in Madrid.
• Results will be presented Oct. 25 in metastatic NSCLC, covering first-line PD-L1-negative non-squamous disease and post-EGFR-TKI EGFR-mutated patients.
• Another Phase 3 readout in previously treated advanced or recurrent endometrial cancer is scheduled for Oct. 26 in a Presidential Symposium slot.
• The selections position sacituzumab tirumotecan for higher clinical visibility in large tumor markets, supporting partnering and commercialization optionality.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN53638) on September 22, 2026, and is solely responsible for the information contained therein.